We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.
We are forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization. Our dedicated team is restless about ensuring our therapies ultimately reach patients with life-limiting diseases.
In spite of the many treatments developed for the neurosciences, there continues to be an immense disease burden on patients and a significant economic impact. Neuroscience has the potential to undergo a transformation. The brain’s complexities and molecular mechanisms — historically challenging to understand — are becoming clearer. Building on this new momentum and scientific understanding, we have a tremendous opportunity to develop and deliver transformative therapies that relieve patients’ overall disease burden.
Total Funding: $64M
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2C
Company Size: 1 to 25
Founded: 2019
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Engrail Therapeutics